Treatment
Apremilast clinical trials
We’re tracking 13 recruiting studies that include Apremilast, each written for real people, not researchers, below.
Recruiting studies
- NCT04227314RecruitingPhase 3
Apremilast vs placebo for severe recurrent mouth ulcers
This Phase 3 trial tests whether apremilast can reduce severe, recurring mouth ulcers compared with an inactive placebo. It aims to improve ulcer frequency and pain while carefully checking safety.
AmiensAges 18 years+ - NCT07337434RecruitingEarly Phase 1
Comparing two pills for moderate to severe psoriasis
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Peshawar, Khyber PukhtunkhwaAges 18–60 - NCT04528082RecruitingPhase 3
Apremilast for children with frequent mouth ulcers from Behçet’s disease
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
BronAges 2–17 - NCT04804553RecruitingPhase 3
Apremilast for children with active juvenile psoriatic arthritis
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
BregenzAges 5–17 - NCT05744466Recruiting
Compare two psoriasis medicines using real-world patient data
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
Waltham, MassachusettsAges 18 years+ - NCT05767047RecruitingPhase 3
Apremilast study for children with mouth ulcers from Behçet’s
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
ThessalonikiAges 5–18 - NCT06509984RecruitingPhase 2
Testing apremilast for genetic EBS with frequent blisters
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
Nice, FranceAges 6–99 - NCT07029529RecruitingPhase 2
Apremilast for alcohol use disorder
This study tests whether a drug called apremilast can help people who drink heavily reduce their alcohol use. You will take the medication daily for several weeks and attend study visits to track your progress.
New Haven, ConnecticutAges 21–65 - NCT07325266RecruitingPhase 2
Testing apremilast for alcohol use disorder
This study tests whether a pill called apremilast can help reduce drinking in people with alcohol use disorder. You'll take the medication and attend regular visits to see how it affects your alcohol cravings and use.
Los Angeles, CaliforniaAges 21 years+ - NCT06593197Enrolling by invitationPhase 4
Apremilast plus light therapy for vitiligo
This study tests whether adding a pill called apremilast to narrowband UVB light therapy works better than light therapy alone for vitiligo. It may help repigment the skin more effectively.
Karachi, SindhAges 18–70 - NCT05703685RecruitingPhase 1
Imaging brain inflammation target in depression with PET
This Phase 1 study uses a PET brain scan tracer to see how a specific brain target (PDE4B) is involved in major depressive disorder (MDD). It’s mainly testing whether the imaging approach works and what it shows in people with depression who meet specific safety and medication rules.
Bethesda, MarylandAges 18–70 - NCT06382987Recruiting
Comparing deucravacitinib vs apremilast for plaque psoriasis
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
Minato-ku, TokyoAges 18 years+ - NCT02735707RecruitingPhase 3
Adaptive trial for severe pneumonia care in intensive care
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Jacksonville, FloridaAges 18 years+
What Apremilast is being studied for
Conditions with recruiting Apremilast studies.
Common questions
- Are there clinical trials studying Apremilast?
- Yes. Clin2 currently lists 13 recruiting studies that include Apremilast, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Apremilast trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Apremilast an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Apremilast or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.